Catalyst

Slingshot members are tracking this event:

Shire reinforces commitment in Hematology with robust data presented at international congress of the World Federation of Hemophilia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SHPG Community voting in process

Additional Information

Additional Relevant Details
Advancing Treatment Approaches to Optimize Patient-Centered Care
During WFH 2016, Shire researchers will address the PROPEL study, which compares the safety and efficacy of ADYNOVATE [Antihemophilic Factor [Recombinant], PEGylated] following pharmacokinetic (PK)-guided prophylaxis targeting two different Factor VIII trough levels. The novel design of the study is built upon preliminary data indicating that maintaining higher trough levels may be able to help enhance bleed protection and help more patients reach zero bleeds.In addition, the company has initiated research on an innovative patient-reported outcome (PRO) measure: Goal Attainment Scaling – Hematology (GOAL-Hēm). The measure is intended to support broader bleeding disorder management by supplementing standard clinical outcome measures with those that are patient-centered, customizable and sensitive to change across patients and patient populations.
https://www.shire.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords World Federation Of Hemophilia, Hematology, Adynovate, Antihemophilic Factor (recombinant), Pegylated, Hemophilia A, Vonvend, Pharmacokinetic-guided Prophylaxis, Goal Attainment Scaling – Hematology